Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma ; volume:13 ; number:5 ; year:2024 ; pages:459-467 ; extent:9
Liver cancer ; 13, Heft 5 (2024), 459-467 (gesamt 9)
- Creator
-
Kudo, Masatoshi
- DOI
-
10.1159/000540801
- URN
-
urn:nbn:de:101:1-2410302322394.736776112024
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kudo, Masatoshi
Other Objects (12)
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis